Pluvicto Treatment

Pluvicto is a targeted radioligand therapy for certain patients with PSMA-positive metastatic castration-resistant prostate cancer. It is different from external beam radiation therapy. External beam radiation treats a defined area from outside the body. Pluvicto is given through an IV and travels through the bloodstream. It attaches to prostate cancer cells that express prostate-specific membrane antigen, known as PSMA, and delivers radiation directly to those cells.

This treatment is used for advanced prostate cancer that has spread and continues to grow despite hormone-based therapy. The exact eligibility depends on the patient’s treatment history, PSMA PET imaging, kidney function, blood counts, disease burden, symptoms, and overall health. Pluvicto is not appropriate for every patient with prostate cancer, but for the right patient, it can provide a targeted internal radiation option when the disease has become resistant to standard hormone therapy.

How Pluvicto Works

Before Pluvicto is considered, the patient undergoes PSMA PET imaging. This scan looks for prostate cancer cells that show PSMA activity. If the cancer does not show enough PSMA uptake, Pluvicto may not be effective because the treatment needs the PSMA target to find cancer cells.

Pluvicto contains lutetium-177 attached to a PSMA-targeting molecule. The targeting portion finds PSMA-positive prostate cancer cells. The lutetium-177 portion gives off radiation over a short distance. This means the treatment can reach cancer cells in multiple areas of the body while limiting exposure to many normal tissues.

A patient-friendly way to explain it is this: Pluvicto acts like a guided delivery system. The PSMA-targeting part helps locate prostate cancer cells, and the radioactive part delivers treatment directly where the target is present. It is not “whole-body radiation” in the usual external-beam sense. It is targeted internal radiation guided by tumor biology.

What Patients Can Expect

Pluvicto is typically given by IV infusion in repeated cycles. A commonly used schedule is one treatment about every 6 weeks, up to 6 doses, depending on response and tolerability. Before each cycle, the care team reviews symptoms, blood counts, kidney function, liver function, medications, and recent imaging when needed.

Because Pluvicto contains radioactive material, patients receive radiation safety instructions after treatment. These may include guidance about hydration, bathroom hygiene, limiting close contact with certain people for a short period, and safe handling of body fluids. The details depend on institutional protocol and the patient’s home situation.

Monitoring is a major part of treatment. Blood counts are checked because bone marrow can be affected. Kidney function is checked because the drug is cleared from the body in part through the urinary system. Dry mouth can occur because salivary glands may take up some PSMA-targeted treatment. Symptoms such as fatigue, nausea, appetite changes, or pain changes are reviewed at each visit.

Side Effects and How We Manage Them

Side effects vary from patient to patient and may depend on prior therapies, bone marrow reserve, kidney function, and extent of metastatic disease.

Possible side effects may include:

• Fatigue
• Dry mouth
• Nausea or reduced appetite
• Constipation or diarrhea
• Anemia or low red blood cell count
• Low white blood cell count or lymphocyte count
• Low platelet count
• Changes in kidney function
• Temporary changes in taste or oral comfort
• Rare serious blood count or kidney-related complications

How we manage these effects:

• We check blood counts before treatment cycles.
• We monitor kidney function and hydration status.
• We may delay treatment if blood counts or kidney function are not safe.
• We provide anti-nausea medication when needed.
• We recommend hydration unless restricted by another physician.
• We suggest saliva substitutes, sugar-free lozenges, oral rinses, and dental care for dry mouth.
• We coordinate with medical oncology if systemic therapy timing needs to be adjusted.
• We provide radiation safety instructions in clear, practical steps.
• We monitor symptoms between cycles so supportive care can be started early.

Pluvicto is a specialized treatment that requires careful patient selection, imaging review, and follow-up. For men with PSMA-positive metastatic castration-resistant prostate cancer, it may offer a targeted treatment option when disease has progressed despite prior therapy.

Call 847-698-0600 ext. 112 to schedule a consultation.